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SObjective: Although positive pleural lavage cytology (PLC) has been demonstrated to be closely associated
with a poor prognosis for patients with lung cancer, it has not been incorporated into the TNM staging system
of the Union for International Cancer Control. The aim of our study was to retrospectively examine the clinical
significance of PLC status and illustrate the recommendations of the International Pleural Lavage Cytology
Collaborators (IPLCC) in a large national database.
Methods: The Japanese Joint Committee of Lung Cancer Registry database included 11,073 patients with
non–small cell lung cancer who underwent resections in 2004. We extracted the clinicopathologic data for
4171 patients (37.3%) who underwent PLC. These patients were staged according to the seventh edition of
the Union for International Cancer Control TNM classification and by recommendations of the IPLCC, in which
T was singly upgraded up to a maximum of T4 for those who were PLC-positive. Prognoses based on these 2
systems were compared.
Results: A total of 217 patients (5.2%) were PLC-positive, which was significantly associated with a higher
incidence of adenocarcinoma and advanced disease. The 5-year survival for patients with positive and negative
PLC results were 44.5% and 72.8%, respectively, and this difference in survival was statistically significant
(P<.001). Multivariate analysis showed that positive PLC status was an independent factor for a poor prognosis
(hazard ratio, 1.57; P<.001). Significant differences in survival were also found between patients with positive
and negative PLC results in the same T categories and stages, including T2a, T3, stage IB, and stage IIIA.
The IPLCC recommendations adjusted the prognostic differences in all T categories and stages. The significant
difference in survival disappeared between the 2 groups in all T categories and stages.
Conclusions: Our results indicate that a T category upgrade is prognostically adequate for patients who are
PLC-positive. (J Thorac Cardiovasc Surg 2014;148:2659-64)See related commentary on pages 2665-6.
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The Journal of Thoracic and CarFor surgical cases of primary lung cancer, pleural lavage
cytology (PLC) is a simple, easily done technique that
provides a cytodiagnosis at the time of thoracotomy to
evaluate subclinical pleural dissemination of cancer
cells without pleural dissemination or pleural effusion.
After a PLC result was first reported by Eagan and
colleagues1 in 1984, numerous studies have shown that
PLC status is a prognostic factor for primary lung
cancer.2-22 In general, the frequency of positive results
is <10% of patients who underwent PLC in the larger
published series. In previous multiinstitution studies,
a positive PLC result was suggested to be an independent
prognostic factor and a predictor of tumor recurrence.22-26
However, PLC findings were not incorporated in the TNM
Classification of Malignant Tumours.27,28 In 2010, thediovascular Surgery c Volume 148, Number 6 2659
Abbreviations and Acronyms
IPLCC ¼ International Pleural Lavage Cytology
Collaborators
NSCLC ¼ non–small cell lung cancer
PLC ¼ pleural lavage cytology
UICC ¼ Union for International Cancer Control
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SInternational Pleural Lavage Cytology Collaborators
(IPLCC) reported the results of a meta-analysis and
recommended that a single increase in the T category up to
a maximum of T4 be assigned to patients with positive PLC
results.24
The aim of our study was to retrospectively examine the
clinical significance of PLC status and to illustrate the
recommendations of the IPLCC. We used a large national
database that were compiled by the Japanese Joint
Committee of Lung Cancer Registry.29,30PATIENTS AND METHODS
In 2010, the Japanese Joint Committee of Lung Cancer Registry
performed a nationwide retrospective registry study on the prognosis and
clinicopathologic profiles of resected lung neoplasms in Japan.29,30 Only
primary lung neoplasms that had been resected in 2004 at certified
teaching hospitals in Japan were considered for the registry, which
provided a follow-up period of at least 5 years. The committee received
the registries of 11,663 patients from 253 teaching hospitals.
This registry followed the ethical guidelines for epidemiologic studies
published jointly by the Japan Ministry of Science, Culture, and Education
and the Japan Ministry of Health, Labor, and Welfare published June 17,
2002, which were revised August 16, 2007. In addition, it was approved
by the institutional review board of Osaka University Medical Hospital,
where the registry office is located, after discussions were published
August 13, 2009 (approval No. 09124).
The patients in this study were 4171 patients who underwent PLC from
among 11,073 patients with non–small cell lung cancer (NSCLC) (37.3%).
Cases involving malignant pleural effusion were excluded. There were
2524 men and 1647 women. Adenocarcinoma was detected in 2977
patients, squamous cell carcinoma in 881 patients, large cell carcinoma in
149 patients, adenosquamous carcinoma in 81 patients, and other histologic
types in 83patients. The seventh edition of theUnion for International Cancer
Control (UICC) TNM classification system was used for the evaluations of
TNM staging.28 There were 1694 patients in stage IA, 1009 patients in stage
IB, 378 patients in stage IIA, 262 patients in stage IIB, 703 patients in stage
IIIA, 38 patients in stage IIIB, and 87 patients in stage IV. In our study, the
PLC technique used had not been standardized. Induction therapy was
performed in 199 patients (chemotherapy in 118 patients, radiation therapy
in 6 patients, and chemoradiotherapy in 75 patients). Adjuvant chemotherapy
was administered to 977 patients. These menus were not uniform.
Tocorrect the prognoses according to the pathologic stages of patientswith
positive PLC results to patients with negative PLC results, pathologic stages
were reevaluated based on the recommendations of the IPLCC: a single
increase in the p-T category up to a maximum of T4 was assigned to patients
with a positive PLC result (upstage).24 Single increases in the T category
upstaged T1a to T1b, T1b to T2a, T2a to T2b, T2b to T3, and T3 to T4.
Pathologic stages were rearranged according to the upstaged T categories.
Categorical data are presented as frequency and continuous data are
presented as means with standard deviations. Comparisons of categorical
data between the 2 groups were made using c2 tests or Fisher exact tests2660 The Journal of Thoracic and Cardiovascular Surwhere appropriate and continuous data were compared using 2-tailed
t test. The survival time was measured from the date of surgery to the death
date or the last follow-up date. The survival curves were estimated by using
the Kaplan-Meier method. Differences in survival were assessed by the
log-rank test. Multivariate analyses of prognostic factors were carried out
using Cox proportional hazard regression models. A P value<.05 was
considered to be significant.
RESULTS
Among 4171 patients who underwent PLC, 217 patients
(5.2%) had positive PLC results (Table 1). Patients with
positive PLC results had larger tumors (P< .0001) and
more frequently adenocarcinoma in the histology
(P < .0001), advanced stage (P < .0001), and pleural
invasion (P< .0001) in comparison with those who were
PLC-negative.
Sixty-five percent of patients with positive PLC and
29.2% of PLC-negative patients developed recurrence
within 5 years after surgery (P<.0001). The 5-year survival
was 44.5% for patients with positive PLC results and
was 72.8% for patients with negative PLC results
(P< .0001) (Figure 1). By multivariate analysis using a
Cox proportional hazard regression model, PLC status
(hazard ratio, 1.57; 95% confidence interval, 1.276-1.919;
P < .0001) and other clinical factors (ie, gender, age,
T category, N category, M category, and tumor size) were
independent prognostic factors (Table 2).
Comparisons of the survival between patients with
positive and negative PLC results according to T categories
revealed significant differences in T2a (P < .0001) and
T3 (P ¼ .0184) (Figure 2 and Table 3). In addition,
comparisons of the survival between patients with positive
and negative PLC results according to pathologic stages
revealed significant differences in stage IB (P ¼ .0062)
and stage IIIA (P ¼ .0115) (Table 3). Based on the
recommendations of the IPLCC, if a single increase in the
T category up to a maximum of T4 was assigned to a
patient with a positive PLC result, the significant difference
in survival disappeared between the 2 groups in all
T categories and stages. (Figure 3 and Table 4).
DISCUSSION
Body cavity fluid cytology is a simple, easily done
technique that provides an intraoperative cytodiagnostic
evaluation of latent dissemination of cancer cells.31 In
surgical cases of abdominal malignant tumors, PLC status
is an independent prognostic factor, as reflected in the
UICC TNM classification for gastric, uterine, ovarian, and
fallopian tube cancers.28 PLC status is directly involved in
the treatment strategy. However, PLC findings were not
incorporated in the seventh edition of the UICC TNM
staging system.28,32 It is not known to what extent the
noninclusion of PLC results affects treatment strategies.
In this study, 5.2% of patients who underwent PLC had
positive results. When these patients were examined by T,gery c December 2014
TABLE 1. Clinicopathologic characteristics according to pleural
lavage cytology (PLC) results
Characteristic Positive PLC Negative PLC P value
Age (y) 66.2  9.9 66.3  9.8 .9040
Gender .0640
Male 118 2406
Female 99 1548
Histologic type <.0001
Adenocarcinoma 193 2784
Squamous cell carcinoma 19 862
Others 5 308
Surgical procedure .0460
Pneumonectomy 9 121
Lobectomy 177 3239
Segmentectomy 14 321
Wedge resection 10 234
Others 7 38
T category <.0001
T1a 14 1147
T1b 12 771
T2a 138 1390
T2b 9 186
T3 35 394
T4 9 66
N category <.0001
N0 109 3040
N1 26 318
N2 81 584
N3 1 12
M category <.0001
M0 187 3886
M1a 27 30
M1b 3 38
Pathologic stage <.0001
IA 15 1679
IB 60 949
IIA 23 355
IIB 12 250
IIIA 74 629
IIIB 4 34
IV 29 58
Tumor size (cm) 3.40  1.63 2.99  1.80
Pleural factor <.0001
pl 0 47 2759
pl 1 56 669
pl 2 85 229
pl 3 25 279
Not evaluated 4 18
Total 217 3954
PLC, Pleural lavage cytology.
FIGURE 1. Postoperative survival curves based on pleural lavage
cytology (PLC) status. There was a significant difference between patients
with positive and negative PLC results (P<.0001). The solid line indicates
patientswith positive PLC results and the dashed line indicates patientswith
negative PLC results. The vertical bars indicate 95% confidence intervals.
TABLE 2. Multivariate analysis for prognostic factors
Prognostic factor Hazard ratio 95% Confidence interval P value
Positive PLC 1.57 1.276-1.919 <.0001
Male gender 1.66 1.460-1.894 <.0001
Age, per year 1.03 1.023-1.036 <.0001
T category
T1a 1.00 — —
T1b 1.59 1.266-1.990 <.0001
T2a 2.01 1.645-2.461 <.0001
T2b 2.79 2.048-3.794 <.0001
T3 2.94 2.271-3.807 <.0001
T4 3.87 2.692-5.564 <.0001
N category
N0 1.00 — —
N1 1.76 1.459-2.111 <.0001
N2 3.13 2.735-3.580 <.0001
N3 9.27 5.083-16.913 <.0001
M category
M0 1.00 — —
M1a 1.89 1.349-2.643 <.0001
M1b 4.02 2.601-6.206 <.0001
Tumor size (cm) 1.05 1.014-1.085 .006
PLC, Pleural lavage cytology.
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SN, and M categories and by pathologic stages, significantly
higher percentages of advanced cases were seen among
patients with positive PLC results compared with patients
with negative PLC results. Patients with positive PLC
results also had significantly larger tumors than those who
were PLC-negative. A significantly higher percentage ofThe Journal of Thoracic and Carpleural invasion was evident among patients with positive
PLC results compared with those who were PLC-
negative. These characteristics are consistent with those
described in previous reports.1,9,10,12,14,19 In our study, the
5-year survival was 44.5% for patients with positive PLC
results and 72.8% for patients with negative PLC results,
which indicated a significantly worse prognosis for
patients with positive PLC results. A multivariate analysis
revealed that PLC finding is an independent prognosticdiovascular Surgery c Volume 148, Number 6 2661
FIGURE 2. Comparisons of survival curves between patients with positive and negative pleural lavage cytology (PLC) results based on T categories.
A, There was a significant difference between PLC-positive T2a and PLC-negative T2a (P< .0001). B, There was a significant difference between
PLC-positive T3 and PLC-negative T3 (P ¼ .2261). Solid lines indicate patients with positive PLC results and dashed lines indicate patients with negative
PLC results. The vertical bars indicate 95% confidence intervals.
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Sfactor with a hazard ratio of 1.57. PLC status has been
suggested to be an independent prognostic factor in
previous reports.6,12,14,16,19,21 Some reports only
recognized certain stages as an independent factor and
other reports stated that PLC status was not an
independent prognostic factor.17,18 Recent studies that
used meta-analyses have shown that PLC status is an inde-
pendent prognostic factor.23,24,26 However the time periods
considered in these studies covered a wide range. In our
study, patients were limited to those who underwent
surgery during 2004; thus, patients were evaluated and
treated according to a relatively standardized procedure.
The prognoses for patients with positive and negative
PLC results were compared by T category and pathologicTABLE 3. Comparisons of survival rates between patients with
positive and negative pleural lavage cytology (PLC), according to T
categories and pathologic stages
Category or stage
Positive PLC Negative PLC
P valuen
5-y
survival (%) n
5-y
survival (%)
T category
T1a 14 76.2 1147 88.3 .2977
T1b 12 71.3 771 79.2 .1951
T2a 138 45.1 1390 67.7 <.0001
T2b 9 25.0 186 53.7 .1100
T3 35 27.7 394 46.4 .0184
T4 9 19.4 66 36.2 .9587
Pathologic stage
IA 15 100 1679 88.8 —
IB 60 61.5 949 77.1 .0062
IIA 23 48.3 355 62.9 .0833
IIB 12 37.0 250 51.8 .5496
IIIA 74 26.4 629 42.5 .0115
IIIB 4 37.5 34 20.2 .2912
IV 29 27.8 58 30.3 .4962
Total 217 44.5 3954 72.8 <.0001
PLC, Pleural lavage cytology.
2662 The Journal of Thoracic and Cardiovascular Surstage based on the seventh edition of the UICC TNM
classification. Significant differences in survival were found
between the patients with positive and negative PLC results
within the same T category and stage, including T2a, T3,
stage IB, and stage IIIA. One reason for these findings
may be differences in the number of patients in each group.
For example, the T2a and T3 stages included more patients
than the other T subclassifications. Similarly, the stage IB
and stage IIIA categories included more patients than the
other subgroups. Based on the sixth edition of the UICC
TNM classification, the IPLCC recommended that a single
increase in the T category up to a maximum of T4 be
assigned to thosewith positive PLC results.24We performed
a single increase in the T category based on the seventh
edition of the TNM classification. The significant
differences in the survival between patients with positive
and negative PLC results disappeared for all T categories
and stages.
The significance of incorporating PLC findings into the
TNM classification system is reflected in the treatments
for upstaged patients, such as the addition of adjuvant
therapy or a change to a more effective adjuvant therapy.
There have been some proposals for incorporating PLC
findings in the TNM classification system in which patients
with positive PLC results were classified into T3 disease,25
T4 disease,9,21 or stage IIIB disease.14 However there was
no consensus among these proposals because most of these
series were too small for detailed analysis. Moreover,
because PLC status is related to multiple prognostic factors,
it may be inappropriate for patients with positive PLC
results to be classified into a single T category or single
stage. The IPLCC recommendation should be the most
reliable proposal because it is based on an exploratory
statistical model using data from a multiinstitution study.
This study is associated with several limitations that
should be considered when interpreting the results. First,
the PLC technique has not been standardized. The IPLCC
recommends that 100 mL saline be irrigated over the lunggery c December 2014
FIGURE 3. Comparisons of survival curves between patients with positive and negative pleural lavage cytology (PLC) results according to reevaluations
based on International Pleural Lavage Cytology Collaborators recommendations. A, There was no significant difference between PLC-positive upstaged T3
and PLC-negative T3. B, There was no significant difference between PLC-positive upstaged T4 and PLC-negative T4. Solid lines indicate patients with
positive PLC results and dashed lines indicate patients with negative PLC results. The vertical bars indicate 95% confidence intervals.
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Ssurface immediately after thoracotomy and before lung
resection, after which the saline is aspirated and a sample
is sent for cytologic screening for malignant cells.24 In addi-
tion, patients with positive PLC results after pulmonary
resection have a worse prognosis than those with positive
PLC results immediately after thoracotomy.16,20,21 The
finding of a positive PLC result after pulmonary resection
is thought to involve human factors associated with
surgical manipulation,11 and the PLC results obtained
immediately after thoracotomy may more accurately reflect
the biologic malignancy of lung cancer. Second, only
37.3% of NSCLC patients had PLC in this study. One
reason for this finding is that the value of PLC has not
been recognized in many institutions. In our study, patients
who underwent PLC were not compared with the excludedTABLE 4. Comparisons of survival rates between patients with
positive and negative pleural lavage cytology (PLC), according to
upstaged T categories and reevaluated pathologic stages
Category or stage
Positive PLC Negative PLC
P valuen
5-y
survival (%) n
5-y
survival (%)
Upstaged T category
T1a — — 1147 88.3 —
T1b 14 76.2 771 79.2 .9417
T2a 12 71.3 1390 67.7 .7518
T2b 138 45.1 186 53.7 .2261
T3 9 25.0 394 46.4 .2568
T4 44 27.6 66 36.2 .4512
Reevaluated pathologic stage
IA 8 100 1679 88.8 —
IB 7 100 949 77.1 —
IIA 62 61.2 355 62.9 .8223
IIB 21 48.0 250 51.8 .6953
IIIA 70 29.6 629 42.5 .1234
IIIB 20 23.6 34 20.2 .8662
IV 29 27.8 58 30.3 .4962
Total 217 44.5 3954 72.8 <.0001
PLC, Pleural lavage cytology.
The Journal of Thoracic and Carpatients. However, 94.8% of patients who underwent PLC
were PLC-negative, with clinicopathologic characteristics
similar to those of general NSCLC patients. Third, the pa-
tients with positive PLC results were significantly different
from those with negative PLC results. Matching may
equalize this inequality and permit true exploration of the
effects of PLC in similar patients. However, we did not
match the patients because the aim of our study was to
retrospectively examine the clinical significance of the
PLC status and illustrate the recommendations of the
IPLCC based on an exploratory statistical model using
data obtained from a multiinstitution study.24 Fourth, we
did not investigate the incidence of pleural recurrence,
although PLC-positive patients had more episodes of
recurrence than PLC-negative patients within 5 years after
surgery. Patients with positive PLC results have been
reported to have a high incidence of pleural recur-
rence.19,25,26,33 Other reports have indicated that local
intrapleural therapy is effective for local control, although
this treatment does not improve survival.18,34 Because the
PLC findings affect all T, N, and M categories, the
administration of systemic adjuvant chemotherapy may be
effective in patients with positive PLC results. The
importance of incorporating PLC results into the TNM
classification will be recognized only if the effectiveness
of adjuvant chemotherapy is demonstrated prospectively
in patients with positive PLC results.CONCLUSIONS
PLC status was an independent prognostic factor in
patients with NSCLC who had been surgically treated.
Based on the recommendations of the IPLCC, if a single
increase in the T category up to a maximum of T4 is
assigned to a patient with a positive PLC result, the
significant difference in survival disappears between the 2
groups in all T categories and stages. This recommendation
appears to be an appropriate method for incorporating
PLC findings into the seventh edition of the UICC TNMdiovascular Surgery c Volume 148, Number 6 2663
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Sclassification. The implications of incorporating PLC
findings into the TNM classification system is reflected in
the treatments for upstaged patients, such as the addition
of adjuvant therapy or a change to a more effective adjuvant
therapy.
We hope that PLC findings will be incorporated in the
next revision of the UICC TNM classification.
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